Keyword Search
PRESS RELEASE
Mar 17, 2026
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
PRESS RELEASE
Mar 06, 2026
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
PRESS RELEASE
Mar 02, 2026
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
PRESS RELEASE
Feb 26, 2026
Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
PRESS RELEASE
Feb 12, 2026
Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time
PRESS RELEASE
Jan 02, 2026